Abstract:Background Radiotherapy is one of the most important therapeutic strategies for treating cancer. For decades, studies concerning the outcomes of radiotherapy mainly focused on the biological effects of radiation on tumor cells. Recently, we have increasingly recognized that the complex cellular interactions within the tumor microenvironment (TME) are closely related to treatment outcomes. Main content As a critical component of the TME, fibroblasts participate in all stages of cancer progression. Fibroblasts are able to tolerate harsh extracellular environments, which are usually fatal to all other cells. They play pivotal roles in determining the treatment response to chemoradiotherapy. Radiotherapy activates the TME networks by inducing cycling hypoxia, modulating immune reaction, and promoting vascular regeneration, inflammation and fibrosis. While a number of studies claim that radiotherapy affects fibroblasts negatively through growth arrest and cell senescence, others argue that exposure to radiation can induce an activated phenotype in fibroblasts. These cells take an active part in constructing the tumor microenvironment by secreting cytokines and degradative enzymes. Current strategies that aim to inhibit activated fibroblasts mainly focus on four aspects: elimination, normalization, paracrine signaling blockade and extracellular matrix inhibition. This review will describe the direct cellular effects of radiotherapy on fibroblasts and the underlying genetic changes. We will also discuss the impact of fibroblasts on cancer cells during radiotherapy and the potential value of targeting fibroblasts to enhance the clinical outcome of radiotherapy. Conclusion This review provides good preliminary data to elucidate the biological roles of CAFs in radiotherapy and the clinical value of targeting CAFs as a supplementary treatment to conventional radiotherapy. Further studies to validate this strategy in more physiological models may be required before clinical trial.

Targeting Tumor Physical Microenvironment for Improved Radiotherapy

Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities

Tumor Microenvironment‐Enabled Nanotherapy

Nanotherapy Targeting the Tumor Microenvironment

Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment

The post-chemotherapy changes of tumor physical microenvironment: Targeting extracellular matrix to address chemoresistance

Tumor Therapy Strategies Based on Microenvironment‐Specific Responsive Nanomaterials

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy

Recent Progress of the Tumor Microenvironmental Metabolism in Cervical Cancer Radioresistance

Tumor Microenvironment and Tumor Targeting Therapy

Tackling the Tumor Microenvironment： What Challenge Does It Pose to Anticancer Therapies？

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Effects of Radiation Therapy on Tumor Microenvironment: an Updated Review

Nanoparticles Targeting and Remodeling Tumor Microenvironment for Cancer Theranostics.

Role of tumor microenvironment in cancer progression and therapeutic strategy

Targeting Tumor Microenvironment for Cancer Therapy

Radiotherapy-activated tumor immune microenvironment: Realizing radiotherapy-immunity combination therapy strategies

Advances in targeting tumor microenvironment for immunotherapy